Tag: Nanolek

NANOLEK is a Russian biopharmaceutical company with its own high-tech complete cycle production corresponding to the GMP and ISO standards and with RUSNANO among the shareholders.

NANOLEK specializes in the production of import-substituting and innovative pharmaceuticals, both in-house developed and invented with the help of international partners, with a focus on the prevention and treatment of socially significant diseases.

Biomedical complex “NANOLEK” includes three independent production buildings. The plant was built and designed from the ground up under the priority areas of the product portfolio:
1) production of solid dosage forms (antiretroviral therapy, oncology and cardiovascular diseases);
2) biotechnology production in syringes and vials.

From the localization of import substituted drugs to the manufacture of domestic innovative drug development.

Nanolek is implementing its strategy in two stages, while adhering to state priorities for the development of the domestic pharmaceutical industry and the Pharma-2020 strategy.

At the first stage (2012-2017), the NANOLEK’s activity was focused on the priorities of the state policy in the field of import substitution and was aimed at localization on the basis of the production site of the company in the Kirov region producing the most popular high-tech medicines, including those never-before-produced in the Russian Federation.

The next stage (2018-2022) will be introducing to market innovative high-tech in-house developed products, the work on which is being conducted in association with leading Russian research institutes and leading foreign research companies.

Nanolek and Merck Launched Full Production Cycle for CVD Treatment

The biopharmaceutical company Nanolek together with Merck launches the production of a medicinal product for the treatment of cardiovascular diseases (CVD) in the Kirov region. The official start o...

Nanolek Launched First Labeled Commercial Batch of Orphan Drug

NANOLEK Company has successfully implemented all the necessary hardware and software for labeling for production. Thanks to the measures taken, the company managed to start the process in a planned...

Sanofi and Nanolek Begin Localisation of Menactra Vaccine

Sanofi and Nanolek announced a new stage in the development of a long-term partnership - the beginning of a project to localize the production of Menactra® vaccine. The partnership will help expand th...

Janssen and Nanolek Announce Localization of Darzalex in Russia

Janssen, the pharmaceutical division of Johnson & Johnson LLC, and the Russian biopharmaceutical company Nanolek announce the localization in Russia of the production of Darzalex® (daratumumab) us...

Nanolek Expanding to CIS Countries Markets

The Nanolek Company enters the markets of the CIS countries by registering three retail drugs against allergies and for the treatment of cardiovascular diseases in Azerbaijan. There, the company hopes...

GSK Vaccines to be Produced at NANOLEK’s Facilities

GSK International Research Pharmaceutical Company and Russian biopharmaceutical company NANOLEK announced a long-term strategic partnership, under which GSK vaccines will be produced at NANOLEK's faci...

Nanolek to Complete Sanofi Vaccine Localization by 2022

Nanolek plans to launch the full-cycle production of a 5-in-1 infant vaccine under a technology transfer project with Sanofi Pasteur (France) by 2022. The first phase in the project to localize the...

Kirov pharma cluster participants explored biotech development in France

The delegation of the government of the Kirov region visited the Lyonbiopôle in France, which is largest pharmaceutical cluster in the world.

Russian Ministry included the Kirov region biotech cluster in its register

The industrial cluster became the first in the region to have been included in the list of industrial clusters and specialized organizations of industrial clusters of the Ministry of Industry and Trade of Russia.

Nanolek registers new drug to treat Hunter syndrome in Russia

Idursulfase beta, an original drug for the treatment of Hunter syndrome, a rare disease, was registered in Russia by Nanolek, a biopharmaceutical company, in cooperation with Green Cross, a South Korean company.

In 2017 Nanolek demonstrates the first results of its active market development

In 2017, the revenue of Nanolek LLC reached 2.6 billion rubles, which is a 3-fold increase compared to 2016. The output of medicinal products at the Nanolek plant in the Kirov region amounted to 8.1 million packages.

Merck will promote its products in Russia independently

Merck KGaA
Merck KGaA announced that, from January 1, 2018 the distribution and marketing rights for its cardiovascular drugs and cerebrovascular drugs in Russia transferred to Merck LLC

NANOLEK will cover the needs for inactivated polio vaccine in Russia

Polymilex, an inactivated polio vaccine, is the first IPV fully manufactured in Russia

NANOLEK becomes the first Russian partner of SK Chemicals from Korea

NANOLEK announced its cooperation in the area of joint research, development, and manufacturing of vaccines with SK Chemicals

In 2018 Nanolek will fully cover the needs of Russian market in IPV

Today the world faces problems in meeting the demand for inactivated polio vaccine (IPV) which can be explained by increased global needs in this medicine

Authorities select pharmaceutical companies for participation in Kirov cluster

The Government of the Kirov region held a meeting of its working group on the formation of industrial cluster